Progress in neuro-psychopharmacology & biological psychiatry
April 2, 2025
Simon Reiche, Tim Hirschfeld, Anna Lena Gröticke et al.
5 citations
Evidence on the neuropsychological consequences of classic psychedelics like psilocybin, LSD, and ayahuasca is conflicting, and little is known about how sporadic use of psychedelics under naturalistic conditions may affect cognitive functioning. Given the growing interest in the therapeutic potential of psychedelics and the rise in non-medical use, further exploration into their...
Current Topics in Behavioral Neurosciences
2025
Tim Hirschfeld, Felix Blei, Lavinia Stegemann et al.
1 citation
Classic psychedelics such as LSD, psilocybin, and DMT from unregulated markets pose considerable risks through unknown adulterants and potencies. In this chapter, we explore the importance of drug checking in minimizing harm among users of classic psychedelics and examine the opportunities and challenges associated with intervention settings, analytical techniques, and risk communication...
May 3, 2024
Kasey Devitt, Johanna Prugger, Tim Hirschfeld et al.
preprint
The open data initiative Altered States Database (ASDB) collects psychometric questionnaire data on the subjective experiences of pharmacologically and non-pharmacologically induced altered states of consciousness. The ASDB is updated yearly and can be utilized by both researchers and non-scientists to access information or undertake further work on the data. The current update adds data...
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
October 1, 2023
Tim Hirschfeld, Johanna Prugger, Tomislav Majić et al.
24 citations
Lysergic acid diethylamide (LSD) is a potent classic serotonergic psychedelic, which facilitates a variety of altered states of consciousness. Here we present the first meta-analysis establishing dose-response relationship estimates of the altered states of consciousness induced by LSD. Data extracted from articles identified by a systematic literature review following PRISMA guidelines were...
Journal of Psychopharmacology
March 4, 2021
Tim Hirschfeld, Timo T Schmidt
90 citations
Background: Psilocybin is the psychoactive component in Psilocybe mushrooms (‘magic mushrooms’). Whether and how the quality of the psilocybin-induced experience might mediate beneficial health outcomes is currently under investigation, for example, in therapeutic applications. However, to date, no meta-analysis has investigated the dose-dependency of subjective experiences across available...
2021
Daan van der Gouwe, Tim Hirschfeld, Tomislav Majić et al.
Purpose of Review With the continuous emergence of new psychoactive substances, drug checking (DC) services are challenged by an increasingly complex drug market. Considering the resumed scientific and public interest in serotonergic psychedelics (SPs) like LSD, psilocybin, and 2C-B, we present the results of a literature search investigating the presence and proportion of SPs in DC samples....
bioRxiv (Cold Spring Harbor Laboratory)
June 11, 2020
Tim Hirschfeld, Timo Torsten Schmidt
8 citations
preprint
Abstract Psilocybin is the active component of magic mushrooms and is well known for its psychoactive properties. Different questionnaires have been developed to systematically quantify altered states of consciousness induced by psychoactive drugs. The aim of this study was to obtain the dose-response relationships of the subjective experiences induced by psilocybin in healthy study...